Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2014-10-28
2021-09-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Part 1 will be the dose escalation portion of this study to determine the maximum tolerated dose in subjects with solid tumors, and
2. Part 2 will comprise cohort expansions to further characterize the safety and tolerability of E7090 and to assess preliminary efficacy of E7090 in subjects with solid tumors characterized by genetic abnormalities in FGF/FGFR pathway.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
NCT00280397
A Study of E7130 in Participants With Solid Tumors
NCT03444701
A Study of E7080 in Subjects With Solid Tumor
NCT01268293
Phase I Clinical Study of E7389
NCT00326950
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
NCT00921869
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
E7090 Arm
Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
E7090
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E7090
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female subjects age \>= 20 years at the time of informed consent
3. Subjects with a histological and/or cytological diagnosis of solid tumor
4. Subjects who failed standard therapies, or for which no appropriate treatment is available.
5. Subjects with Performance Status (PS) score of 0-1 established by Eastern Cooperative Oncology Group (ECOG)
6. Subjects who are expected to survive for 3 months or longer after starting administration of the investigational drug.
7. Subjects with tumor expressing genetic abnormality in FGF/FGFR (fibroblast growth factor/ fibroblast growth factor receptor)pathway.
Exclusion Criteria
2. Medical history of clinically significant cardiovascular impairment
3. Concomitant systemic infection requiring medical treatment
4. Effusion requiring drainage
5. Known intolerance to the study drug (or any of excipients)
6. Subjects whose toxicity of previous treatment has not recovered to Grade 1 or lower (except for alopecia).
7. Inability to take oral medication, or malabsorption syndrome, or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of E7090.
8. Psychiatric disorder (e.g., alcohol or drug dependency) judged to be ineligible for study entry by the investigator or subinvestigator
9. Females who are pregnant or breastfeeding
10. Any subjects who are judged by the principal investigator or the other investigators to be inappropriate as subjects in this clinical study.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eisai Trial Site #1
Nagoya, Aichi-ken, Japan
Eisai Trial Site #1
Kashiwa, Chiba, Japan
Eisai Trial Site #1
Matsuyama, Ehime, Japan
Eisai Trial Site #1
Sapporo, Hokkaido, Japan
Eisai Trial Site #1
Amagasaki, Hyōgo, Japan
Eisai Trial Site #1
Tsukuba, Ibaraki, Japan
Eisai Trial Site #1
Kawasaki, Kanagawa, Japan
Eisai Trial Site #1
Yokohama, Kanagawa, Japan
Eisai Trial Site #1
Chuo-ku, Niigata, Japan
Eisai Trial Site #1
Kitaadachi, Saitama, Japan
Eisai Trial Site #1
Chuo-Ku, Tokyo, Japan
Eisai Trial Site #1
Koto-ku, Tokyo, Japan
Eisai Trial Site #1
Chiba, , Japan
Eisai Trial Site #1
Fukuoka, , Japan
Eisai Trial Site #1
Kyoto, , Japan
Eisai Trial Site #1
Osaka, , Japan
Eisai Trial Site #2
Osaka, , Japan
Eisai Trial Site #3
Osaka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E7090-J081-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.